May 22, 2019 10:20 AM EDT
News Briefing

Ar­ray shares surge as PhI­II sets the stage for FDA fil­ing; FDA gives Avadel pri­or­i­ty re­view

John Carroll

Editor & Founder

→ Shares of Ar­ray Bio­Phar­ma $AR­RY did some bob­bing and weav­ing on Tues­day, but end­ed the day up 23% on pos­i­tive late-stage da­ta from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

FDA plans to ban phar­ma em­ploy­ees from serv­ing on ad­comms. The im­pact will be lim­it­ed

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times